China steps up in­ac­ti­vated COVID-19 vac­cine de­vel­op­ment


China’s in­ac­ti­vated COVID-19 vac­cine is ex­pected to fin­ish clin­i­cal tri­als and get ready for the mar­ket as early as the end of this year or early next year, ac­cord­ing to de­vel­oper China Na­tional Biotec Group (CNBG).

As a sub­sidiary of the China Na­tional Phar­ma­ceu­ti­cal Group (Sinopharm), CNBG has two in­ac­ti­vated COVID-19 vac­cines un­der Phase-2 clin­i­cal tri­als and has in­creased its vac­cine pro­duc­tion ca­pac­ity.

The com­pany said more than 2000 peo­ple have re­ceived the vac­cines and clin­i­cal data has ver­i­fied their safety and ef­fi­cacy, show­ing that ad­verse re­ac­tions are far lower than other sim­i­lar prod­ucts.

To in­crease manufactur­ing ca­pac­ity, the com­pany has built a large pro­duc­tion unit in Bei­jing that can meet high bio-safety pro­tec­tion re­quire­ments.

The unit will be able to pro­duce 100 to 120 mil­lion in­ac­ti­vated COVID-19 vac­cines per year once mass pro­duc­tion be­gins.

An­other vac­cine pro­duc­tion fa­cil­ity in Wuhan is ex­pected to be com­pleted by the end of June or early July.

To­gether, the two pro­duc­tion units are ex­pected to pro­duce 200 mil­lion in­ac­ti­vated COVID-19 vac­cines per year, which will help en­sure ad­e­quate sup­ply.

Newspapers in English

Newspapers from Fiji

© PressReader. All rights reserved.